Iguchi Toshihiro, Arai Yasuaki, Inaba Yoshitaka, Yamaura Hidekazu, Sato Yozo, Miyazaki Masaya, Shimamoto Hiroshi
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Nagoya, Japan.
Cardiovasc Intervent Radiol. 2008 Jan-Feb;31(1):86-90. doi: 10.1007/s00270-007-9189-0. Epub 2007 Oct 10.
We retrospectively evaluated the safety and efficacy of preoperative initial hepatic arterial infusion chemotherapy (HAIC) through a port-catheter system in patients with liver dysfunction due to synchronous and unresectable liver metastases. The aim of HAIC was to improve patients' clinical condition for later surgical removal of primary colorectal cancer.
Port-catheter systems were placed radiologically in 21 patients (mean age 58.6 +/- 8.1 years) with liver dysfunction due to synchronous liver metastases from colorectal cancer. Initial HAIC of 1,000 mg/m(2) 5-fluorouracil was administered weekly as a 5 hr continuous infusion through this system. Surgical removal of the primary lesion was planned after HAIC improved the liver function.
Port-catheter system placement was successful in all patients without severe complications. Patients were followed up for a median of 309 days (range 51-998 days). After starting HAIC, no severe adverse events that caused drug loss and treatment postponement or suspension were observed in any of the patients. HAIC was performed a mean of 4.5 +/- 3.0 times and the liver function improved in all patients. Curative (n = 18) or palliative (n = 1) surgical removal of the primary lesion was performed. The remaining 2 patients died because extrahepatic metastases developed and their performance status worsened; thus, surgery could not be performed. The median survival times of all patients and the operated patients were 309 and 386 days, respectively.
Initial HAIC administration is a safe and efficacious method for improving liver function prior to operative resection of primary colorectal cancer in patients with liver dysfunction due to synchronous and unresectable liver metastases.
我们回顾性评估了经导管肝动脉灌注化疗(HAIC)对因同步性不可切除肝转移导致肝功能障碍患者的安全性和有效性。HAIC的目的是改善患者的临床状况,以便日后手术切除原发性结直肠癌。
通过放射学方法为21例(平均年龄58.6±8.1岁)因结直肠癌同步肝转移导致肝功能障碍的患者放置导管系统。通过该系统每周以5小时持续输注的方式给予1000mg/m²的5-氟尿嘧啶进行初始HAIC。计划在HAIC改善肝功能后手术切除原发性病变。
所有患者导管系统放置均成功,无严重并发症。患者的中位随访时间为309天(范围51-998天)。开始HAIC后,未观察到任何导致药物减量及治疗推迟或中断的严重不良事件。HAIC平均进行4.5±3.0次,所有患者肝功能均得到改善。对原发性病变进行了根治性(n = 18)或姑息性(n = 1)手术切除。其余2例患者因发生肝外转移且身体状况恶化死亡,因此无法进行手术。所有患者及接受手术患者的中位生存时间分别为309天和386天。
对于因同步性不可切除肝转移导致肝功能障碍的患者,术前给予初始HAIC是一种安全有效的方法,可改善肝功能以便进行原发性结直肠癌的手术切除。